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Background/aim: Multiple sclerosis (MS) is an autoimmune disease characterized by neurodegeneration or demyelination; the
relapsing–remitting phase of MS is characterized by acute exacerbation of disease activity. The most commonly used noninvasive
approach to assess autonomic function is the determination of heart rate turbulence (HRT) and heart rate variability (HRV). The aim of
this study was to evaluate the presence of cardiovascular autonomic dysfunction using HRT and HRV parameters determined via 24-h
Holter ECG monitoring in patients with relapsing–remitting MS without known heart disease.
Materials and methods: The study included 26 patients diagnosed with relapsing–remitting MS and 22 age- and sex-matched healthy
controls. HRT and HRV parameters were analyzed via 24-h Holter ECG monitoring. Magnetic resonance imaging findings were
reevaluated to identify any demyelinating lesions in the brain stem.
Results: The HRV parameters of SDNNI (mean of the standard deviations of all normal sinus RR intervals in all 5-min segments),
rMSSD (root–mean–square successive difference), and sNN50 (percentage of successive normal sinus RR intervals >50 ms) were
significantly lower in the MS group than in the control group (P < 0.05).
Conclusion: This study revealed that the patients with MS had reduced HRV; this was demonstrated by dysfunction with regard to
parasympathetic and sympathetic parameters in HRV analysis.
Key words: Multiple sclerosis, arrhythmias, autonomic nervous system disorders

1. Introduction
Multiple sclerosis (MS) is an autoimmune disease that
causes neurodegeneration or demyelination caused by
the entrance of autoreactive lymphocytes into the central
nervous system (CNS). Although the etiology of MS
remains unknown, environmental and genetic factors
are thought to contribute to its development. Multiple
sclerosis (MS) is a rare disease, characterized by a chronic
course with intermittent relapses According to WHO, the
disease burden of MS accounts for 0.1% of total disease
burden of neurologic diseases [1–3]. The course of MS
is explained broadly with two phases: the first phase is
the relapsing–remitting phase, which is characterized by
acute exacerbation of disease activity and is pathologically
associated with CNS inflammation. The second phase
(progressive) involves slow but constant progression of
neurological deficits due to degeneration of the CNS [1].
MS usually begins in the form of the relapsing–remitting

phase, but a few cases may present with the progressive
form at disease onset. The number of relapses, their
frequency, and the development of demyelinating lesions
appear to be predictors of disease progression [4].
Although it is known that autonomic dysfunction
might occur in organs with autonomic nervous system
(ANS) innervation, there are some studies on autonomic
dysfunction in MS. Furthermore, patients with MS
might be completely asymptomatic, particularly in the
steady state, and thus may require active examination
of autonomic dysfunction through ANS testing [5]. The
cardiovascular autonomic system is currently the most
comprehensively researched part of the ANS in patients
with MS, quite possibly due to the ease and reliability of
testing, and also the fact that brain stem lesions may lead
to cardiovascular autonomic dysfunction [6]. The locus
coeruleus is located in the brain stem and is responsible
for the synthesis of norepinephrine. Damage to the locus
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coeruleus might cause sympathetic dysfunction in MS
[7]. Although the parasympathetic system is reportedly
preserved in the initial disease period, as the disease
duration is prolonged, parasympathetic dysfunction may
also be observed [8].
The most common noninvasive methods used to assess
autonomic function are evaluations of heart rate turbulence
(HRT) and heart rate variability (HRV) with 24-h Holter
electrocardiography (ECG) monitoring. HRT refers to
physiological short-term baroreflex-regulated fluctuations
in sinus rhythm following premature ventricular
contraction (PVC) [9]. The fluctuation begins with heart
rate acceleration for a short time and is followed by a slow
decrease through mediation by the baroreflex; it usually
comprises 15–20 consecutive beats [10]. The following
parameters are used to evaluate HRT: (1) turbulence
onset (TO), which reflects the initial heart rate increase
following a ventricular premature beat, and (2) turbulence
slope (TS), which reflects heart rate deceleration [11,12].
Similar to HRT, HRV also provides important data
regarding cardiac autonomic function [13]. HRV is
based on the evaluation of RR intervals (the intervals
between successive heartbeats), and it corresponds to
cyclic fluctuations in resting heart function. Increased
sympathetic activity and withdrawal of vagal tone lead to a
decrease in HRV, which is believed to be a mechanism for
the development of life-threatening arrhythmias [13,14].
The aim of this study was to evaluate the presence of
cardiovascular autonomic dysfunction using HRT and
HRV parameters determined with 24-h Holter ECG
monitoring in patients with MS but no known heart
disease.
2. Materials and methods
2.1. Study design and patient selection
This study was conducted from May 2015 to May 2018 and
included 26 patients diagnosed with MS and 22 volunteers
(controls) without any known cardiovascular diseases who
were similar to the patients in terms of age and sex. Holter
ECG monitoring was performed in the patients included
in the study because of palpitation symptoms; there was no
drug use that would affect HRT and HRV measurements.
Informed consent was obtained from all participants, and
the study was approved by the local ethics committee.
All patients with MS included in this study were in
the relapsing–remitting phase according to the McDonald
criteria [15], and none of the patients had the progressive
course of the disease. All the patients had been diagnosed
with MS within the last 3 years. Additionally, all patients
had sinus rhythm, and none of the patients had any known
cardiovascular disease.
Patients with myocardial infarction, moderate or severe
heart valve diseases, heart rhythm disorders including

atrial fibrillation, congenital heart diseases, diabetes
mellitus, hypertension, or cerebrovascular events, and
those using medications that could affect the autonomic
nervous system (anticholinergics, antiarrhythmics,
sympathomimetics, parasympathomimetics, etc.) were
excluded from the study.
Serum electrolyte values, atrial conduction times
measured in ECG, and echocardiography parameters were
normal in all patients and the control group.
2.2. Measurements
In all patients and controls, 24-h Holter ECG monitoring
was applied (Reynolds Medical Pathfinder Software
Version V8.255; Reynolds Medical, Hertford, UK).
Holter ECG monitoring was applied within 3 days after
performing brain magnetic resonance imaging (MRI)
in the patient group. The Holter records were examined.
Artefacts were excluded manually. As HRT data cannot be
obtained in patients without a PVC, these patients were
excluded from the study.
The HRT parameters (TO and TS) were calculated by
using a computer program (HRT View Software Version
0.60–0.1, Munich, Germany). TO was expressed as the
percentage difference between 2 RR intervals measured
immediately after a VPB and immediately before a VPB.
The TS value was defined and calculated as the maximum
positive slope of a regression curve obtained from any
sequence of 5 subsequent RR intervals within the first
20 sinus rhythm intervals after a VPB. The TO value was
calculated for each VPB separately and the final data was
defined as the mean values of these separate measurements.
A TO value of ≥0% and a TS value of ≤2.5 ms/RR were
considered abnormal [16].
HRV analysis was performed according to the
guidelines of the European Society of Cardiology and the
North American Society of Pacing and Electrophysiology
in all participants, with HRV measurements from 24-h
Holter ECG records [14]. Evaluation of HRV were
performed by using a computer program (Cardioscan
12.0, DMS, Ventura, CA, USA). The nocturnal 6-h part was
determined following the evident day–night switch in the
length of RR intervals. The HRV measurements included
the standard deviation of all normal sinus RR intervals
over 24 h (SDNN), mean of the standard deviations of
all normal sinus RR intervals for all 5-min segments
(SDNNI), standard deviation of the averaged normal
sinus RR intervals for all 5-min segments (SDANN), root–
mean–square of the successive normal sinus RR interval
difference (rMSSD), and percentage of successive normal
sinus RR intervals >50 ms (sNN50).
MRI findings of the patients were reevaluated to
identify any demyelinating lesions in the brain stem. The
results were noted as presence/absence of lesions in the
brain stem.
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2.3. Statistical analysis
All analyses were performed using SPSS software, version
24 (IBM Corp., Armonk, NY, USA). A P-value of <0.05 was
considered significant. The distributions of HRT and HRV
parameters in the MS and control groups were examined
using the Shapiro–Wilk test. Continuous data that did not
show normal distribution were compared using the Mann–
Whitney U test. Categorical parameters were evaluated and
compared with Chi-square tests. HRT and HRV values were
adjusted according to age by analysis of covariance. For
descriptive statistics, frequencies were used for categorical
data and median and interquartile ranges were used for
quantitative data not normally distributed. Correlation
analyses were performed using Spearman’s rank correlation
coefficients. A post-hoc power analysis was performed to
confirm that the current study had adequate power (99%).
3. Results
Of the 26 patients with MS, 6 were male and 20 were female,
and the mean patient age was 43.5 ± 10.7 years (Table 1). In
this group, the mean disease duration after diagnosis at the
time of the study was 2.3 ± 0.6 years. There was no significant

difference in age or sex between the MS and control groups.
Additionally, there was no difference in the mean heart rate
between the 2 groups. Conversely, the HRV parameters
of SDNNI, rMSSD, and sNN50 were significantly lower
in the MS group than in the control group (P = 0.009, P
= 0.011, and P = 0.041, respectively). However, there were
no differences in the other HRV parameters (SDNN and
SDANN) and the HRT parameters (TO and TS) between
the 2 groups (P = 0.373, P = 0.454, P = 0.135, and P = 0.375,
respectively) (Table 2).
There were significant negative correlations between
age and all HRV parameters (Table 3). Furthermore, there
were significant differences in SDNNI, rMSSD, and sNN50
between the 2 groups after adjusting the variables according
to age through analyses of covariance. There were no
significant differences in the nocturnal HRV parameters
between the 2 groups (P = 0.154).
Brain MRI findings revealed brain stem lesions in 13
patients and no brain stem lesions in the remaining 13
patients. There were no significant differences in the HRT
and HRV parameters between patients with and those
without brain stem lesions.

Table 1. Demographic characteristics of the patients with MS and controls.
Patients with MS
(n = 26)

Controls
(n = 22)

P-value

Age (years) (mean ± SD)

43.5 ± 10.7

41.7 ± 9.4

0.311

Sex (number of females)

20 (76.9%)

14 (63.6%)

0.169

MS = multiple sclerosis; SD = standard deviation.
Table 2. HRT and HRV parameters of the patients with MS and controls.

HRT
HRV

Patients with MS
(n = 26)

Controls
(n = 22)

P-value

TO

–0.02 (0.03)

–0.02 (0.05)

0.373

TS

8.04 (13.51)

10.83 (9.34)

0.454

SDNNI

41.00 (18.25)

51.00 (20.50)

0.009*

SDNN

124.50 (51.25)

137.00 (59.25)

0.135

SDANN

117.00 (41.00)

127.50 (60.00)

0.375

rMSSD

20.50 (13.75)

29.50 (20.50)

0.011*

sNN50

2357.50 (6948.25)

5865.50 (12,981.20)

0.041*

Data are presented as median (interquartile range).
HRT = heart rate turbulence; HRV = heart rate variability; MS = multiple sclerosis, TO
= turbulence onset; TS = turbulence slope; SDNN = Standard deviation of NN intervals;
SDNNI = SDNN index; SDANN = Standard deviation of the average NN intervals for each
5-min segment; rMSSD = Root–mean–square of successive RR interval differences; sNN50
= Percentage of successive RR intervals that differ by more than 50 ms.
*P < 0.05.
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Table 3. Correlations of HRV parameters with age.

HRV

r

P

SDNN

–0.386

0.007

SDNNİ

–0.505

<0.001

SDANN

–0.328

0.023

rMSSD

–0.410

0.004

sNN50

–0.504

<0.001

*Spearman’s correlation analysis.

4. Discussion
Autonomic dysfunction is an important symptom as
well as a factor for morbidity among patients with MS.
The limited clinical use of autonomic dysfunction testing
methods in patients with MS makes assessment difficult.
However, the details of these dysfunctions can shed new
light on the management of the disease. In the absence of
reliable methods of measurement for other parameters, the
determination of cardiovascular autonomic dysfunction
using parameters such as HRV and HRT has received
interest [17].
HRV primarily measures tonic vagal activity [18].
Under resting conditions, vagal tone is predominant but
vagal and sympathetic activities are in constant balance.
Reduced HRV is most commonly seen in patients with
heart failure, diabetic neuropathy, or myocardial infarction
[13].
In the present study, the HRV parameters of SDNNI,
rMSSD, and sNN50 were significantly lower in the MS
group than in the control group. These results indicate
autonomic imbalance in patients with MS. However, there
were no significant differences in other HRV parameters
(i.e. SDNN and SDANN) between the groups. A previous
study reported that the value of HRV parameters
decreased as patients with MS aged [19]. In another
study, parasympathetic activity was reported to be lower
in patients who had been living with MS for more than 5
years compared to those who had been diagnosed within
the last 5 years [20]. In the present study, all patients had
been diagnosed with MS within the last 3 years, and HRV
parameters significantly decreased as patient age increased.
This finding supports the theory that parasympathetic
activity decreases and sympathetic activity becomes more
dominant as patients age, regardless of disease duration,
which may seem counterintuitive considering that MS
is a cause of progressive neurodegeneration. However,
in a very recent study that included 43 patients who had
been newly diagnosed with MS, it was reported that 43%
of the patients had autonomic dysfunction as measured
by the Survey of Autonomic Symptoms [21]. Similarly,

when the ANS symptoms of patients with long-standing
MS (n = 33, mean disease duration: 97.6 ± 75.5 months)
were assessed with a battery of tests, a similar frequency
(45.5%) of autonomic abnormality was reported [22].
Even though patient groups were not very large (as is
the case in most studies), these similarities suggest that
the development of ANS problems may not be directly
associated with disease duration (or even progression).
In a seemingly conflicting opinion, Studer et al. suggested
that sympathetic dysfunction was directly associated with
disability progression in MS; however, they also reported
that only patients with the progressive course of disease
demonstrated such a relationship, while those with the
relapsing–remitting course had no differences from
healthy controls in terms of autonomic function [23].
The latter finding requires further analysis, as autonomic
dysfunction was found to be similar to that of controls;
but it is important to note that autonomic dysfunction
was assessed with the head-up tilt test (causing stress)
which may have prevented the detection of underlying
dysfunction which may have been more accurately
determined with 24-h Holter ECG.
Previous studies have reported reduced HRV in
patients with MS in the presence of brain stem lesions, but
this decrease was also associated with general disability,
duration of the disease, and number of recurrences [24–
26]. In the present study, brain MRI revealed brain stem
lesions in half of the patients. In contrast to previous
findings, there were no significant differences in HRT and
HRV parameters between patients with and without brain
stem lesions. This converse result might be due to short
disease duration and the low recurrence rate observed
in our group of patients. Furthermore, considering that
older age significantly influences HRV values in healthy
subjects, it is apparent that further studies should assess
HRV with regard to age groups in patients with MS [27].
HRT impairment reflects cardiac autonomic
dysfunction, particularly in association with impaired
baroreflex sensitivity and decreased parasympathetic
activity. Many previous studies have reported abnormal
HRT in a variety of diseases, and have associated these
findings with impaired ANS and baroreflex response [28–
31]. Despite the presence of studies focused on baroreflex
impairment in MS, to our knowledge, no study has
investigated the relationship between HRT and baroreflex
in patients with MS. The present study is the first to assess
this relationship. Our results pertaining to the comparison
of HRT between patients diagnosed with MS within the
last 3 years and healthy controls revealed no significant
differences between these groups. In contrast to the
findings of previous studies reporting that the baroreflex
is reduced in patients with MS [32,33], the present study
found that the baroreflex is intact, at least during the initial
years of the disease.
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The most significant finding of this study was that
parasympathetic cardiovascular tonus was significantly
lower in patients with MS in the relapsing–remitting
phase than in controls. There are contradictory reports
on the presence and degree of cardiovascular autonomic
dysfunction in patients with MS [23,34]. Adamec et
al. found worse autonomic function in patients with a
progressive course compared to those with relapsing–
remitting course, even when corrections for age, sex,
and disease duration were performed [35]. However, in
an earlier crosssectional study by Flachenecker et al., it
was found that 39% of patients with relapsing–remitting
MS had abnormal sympathetic test results, while no
abnormalities were found in any of the stable MS patients.
Further, even though parasympathetic results were similar
in these 2 groups at baseline, longitudinal analyses showed
that patients demonstrated worsening of parasympathetic
dysfunction, while sympathetic dysfunction was unchanged
hence, supporting our findings [36]. Nevertheless, there
are major differences among studies in the literature and
these discrepancies may have resulted from various causes,
including methodological differences, sample collection/
evaluation, and the clinical state of the patients included
in each study. We believe the main reason for conflicting
results is that previous studies mostly did not consider
the relapsing–remitting phase of the disease, whereas the
present study only included patients in this phase.
The main limitation of our study was the absence of
spectral HRV analysis. Consequently, only parasympathetic

tonus was assessed and sympathetic tonus could not be
evaluated. Another important limitation of our study is
the absence of a gold-standard technique to determine
autonomic activity: we assessed function through
evaluation of HRT and HRV values, which may have
yielded inconsistent results. However, considering that
there is no method to determine autonomic function as a
whole, it is evident that all studies in this field suffer from
this limitation.
In conclusion, despite conflicting results, the present
study has revealed that some HRV values were lower
in patients with MS compared to healthy controls, as
demonstrated by dysfunctional findings with regard
to parasympathetic parameters in HRV analysis. Thus,
patients in the relapsing–remitting phase of MS may
have cardiovascular autonomic dysfunction, but it is
also apparent that there are many contributors to the
dysfunction of the autonomic system. The present findings
need to be confirmed in further studies involving a greater
number of patients who should be stratified with regard to
duration with MS.
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